Bi-directional influences between stress hormones and immune responses have been repeatedly documented, however, in the clinical setting they are rarely considered when immunotherapeutic approaches are used or studied in patients. As some immunotherapeutic treatments have shown great potential in animal models but have had limited success in patients, we hypothesize that ongoing psychological and physiological stress responses in patients, which do not characterize the setting of animal studies, contribute to this discrepancy. In the current study we examined the interaction between ongoing water stress and CpG-C immunotherapy to determine whether stress that precedes immunotherapy can modulate the efficacy of CpG-C immunostimulation. C57BL/6 mice were exposed to water stress or served as controls. Two hours following the commencement of the stress protocol animals were injected with CpG-C, non-CpG, or PBS, and sacrificed 1, 4 or 12 h thereafter. We found that in CpG-C-treated animals stress eliminated the elevation of plasma IL-12, and synergistically elevated corticosterone levels. Furthermore, stress markedly reduced the total number of myeloid (33D1 + ), plasmacytoid (mPDCA-1 + ) and plasmacytoid-derived (33D1 + mPDCA-1 + ) dendritic cells in CpG-C-treated animals, as well as the numbers of these cell sub-types expressing CD11b, CD80 and CD69. These changes were more dramatic in the blood than in the spleen. Overall, these findings indicate that under no-stress conditions CpG-C induces a robust immune response, which is significantly diminished when immunostimulation is attempted during ongoing stress. If these findings hold in humans, potential prophylactic treatments should be found to limit the deleterious effects of ongoing stress on the efficacy of immunotherapy.
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Introduction
The relationship between stress responses and the immune system is bi-directional, as both systems profoundly modulate each other. Certain cytokines have been shown to signal the brain regarding ongoing peripheral immune responses, and consequently bring about the activation of neuroendocrine stress responses (Hickey, 2001; Kusnecov and Goldfarb, 2005; Rossi-George et al., 2005) . Furthermore, activated leukocytes can themselves secrete stress hormones, such as adrenocorticotropic hormone (ACTH) (Blalock et al., 1985) and catecholamines (CAs) (Josefsson et al., 1996) , potentially activating peripheral endocrine responses and directly impacting other cells. Most importantly, activation of the sympathetic nervous system (SNS) and the hypothalamic-pituitary-adrenal (HPA) axis, and the release of their respective stress hormones (e.g., catecholamines and corticosteroids) following stress conditions were shown to modulate immune activity and resistance to cancer progression (Ben-Eliyahu, 2003; Glasner et al., 2010; Shakhar and Blumenfeld, 2003) .
Mechanisms mediating such stress-induced immune regulation include the direct activation of functional receptors for stress hormones expressed by most lymphocytes (Smith and Blalock, 1988) , and the direct sympathetic innervation of primary and secondary lymphoid organs (Elenkov et al., 2000; Sredni-Kenigsbuch, 2002) .
Although this stress-immune relationship has been thoroughly documented, in the clinical setting it is rarely considered when immunotherapeutic approaches are used or studied in patients. The use of immunotherapy in cancer patients has gained momentum in the past decade, as it is now recognized that the patient's immune system has a critical role in shaping malignant development and controlling residual disease (Dunn et al., 2004; Neeson and Paterson, 2006) . However, although pre-clinical studies in animal models showed great potential (Boggio et al., 2000; Brunda et al., 1993; Kobayashi et al., 2002; Zou et al., 1995) , their applications in cancer patients have been less successful (Atkins et al., 1997; Colombo and Trinchieri, 2002; Hurteau et al., 2001; Parris, 2007; Portielje et al., 1999) . Given that immunostimulators act through activating leukocytes, it is feasible that stress hormones would impact leukocytes' responsiveness to immunostimulators. Therefore, it is probable that psychological or physiological stress experienced by patients receiving immunostimulation for a
